Veglin

N/A

Report date: 2022/07/04 19:38:02

NME

Base Information

Drug NameVeglin

Drug Alias NameAS-3VEGF-AS

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 2 antagonists

TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Vascular endothelial growth factor receptor 2

Therapy Area/IndicationsMesothelioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Southern California

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of Southern California

Active IndicationsN/A

Inactive IndicationsMesothelioma

Other Information

ATC CodeN/A